Regulation of the polymeric immunoglobulin receptor and IgA transport: New advances in environmental factors that stimulate pIgR expression and its role in mucosal immunity

Introduction

Secretory IgA (SIgA) is generated by cooperation between two distinct cell types in mucous membranes: plasma cells in the lamina propria that secrete dimeric IgA (dIgA), and epithelial cells that transport the IgA into the lumen. Transcytosis of dIgA through polarized intestinal epithelial cells (IECs) is mediated by the polymeric immunoglobulin receptor (pIgR), an epithelial glycoprotein that picks up its cargo on the basolateral surface and carries it by the process of transcytosis to the apical face. Endoproteolytic cleavage of pIgR near the plasma membrane releases the five extracellular immunoglobulin-like domains of the pIgR, also known as secretory component (SC), into the lumen together with its cargo, thus forming the SIgA complex. Because one molecule of pIgR is consumed with every round of SIgA transport, control of pIgR expression and its epithelial trafficking are critical for regulating the levels of SIgA in external secretions. Here we propose that cross-talk between the commensal microbiota and IECs plays a central role in this regulatory process.

Regulation of pIgR expression by the commensal microbiota

SIgA antibodies in mucosal secretions contribute to immune homeostasis by limiting access of microbial and environmental antigens to the body proper, maintaining the integrity of the epithelial barrier, and shaping the composition of the commensal microbiota.¹ These functions are particularly important in the intestinal tract, home to some 100 trillion bacteria, into which the average human adult secretes up to 3 g of SIgA per day. Accumulating evidence suggests that microbial-associated molecular patterns (MAMPs) stimulate expression of pIgR by IECs, as part of a homeostatic loop in which the microbiota enhances the production of SIgA, which in turn regulates the composition and function of the microbiota. It has long been appreciated that the microbiota plays a critical role in development of the gut-associated immune system, including class switching to IgA and maturation of plasma cells.¹ A direct role for gut bacteria in stimulating pIgR expression was first suggested by the finding that monocolonization of germ-free mice with the commensal bacterium Bacteroides thetaiotaomicron resulted in increased pIgR expression in IECs.² More recently, using a model of reversible colonization of germ-free mice with a non-dividing mutant of Escherichia coli, Hapfelmeier et al. observed a long-lived SIgA response specifically recognizing the inducing bacteria.³ However, exposure of E. coli-colonized mice to other bacteria limited the duration of the SIgA response against the original colonizer, suggesting that the SIgA response adapts to the dominating members of the microbiota. We have compared the composition and compartmentalization of the gut microbiota in wild-type and pIgR knockout (KO) mice, which lack SIgA in gut secretions (Reikvam et al, manuscript in preparation). Interestingly, we found that the diversity of the bacterial community in the cecal lumen was reduced in pIgR KO mice, supporting a role for SIgA in limiting overgrowth of selected species. In contrast, the community of bacteria adherent to the epithelial surface was more diverse in pIgR KO mice than in wild-type mice, and these adherent bacteria caused enhanced expression of several epithelial antimicrobial peptides. These findings suggest that bacteria-specific SIgA anchored in the mucus layer restricts adhesion of bacteria to the epithelial surface and limits bacterial stimulation of host epithelial cells. Under homeostatic conditions, release of MAMPs by SIgA-bound bacteria in the mucus layer may stimulate epithelial cells to produce physiological levels of pIgR, thus enhancing dIgA transport and replenishing SIgA that is lost by mucosal sloughing. Under conditions of suboptimal SIgA production or penetration of the mucus layer by invasive species, direct bacterial stimulation of the epithelial surface could result in enhanced production of pro-inflammatory and antimicrobial products.

A mechanism through which MAMPs may stimulate pIgR expression was suggested by our finding that expression of pIgR was enhanced by stimulation of a human IEC line with double-stranded RNA or lipopolysaccharide (LPS), ligands for Toll-like receptors (TLRs) 3 and 4.^{4, 5} Similar up-regulation of pIgR expression was observed when cells were stimulated with intact reovirus, an intestinal virus with a double-stranded RNA genome,⁶ or bacteria of the family Enterobacteriaceae, which express a form of LPS that stimulates TLR4.⁷ While caution must be observed in the interpretation of experiments using IEC lines that may not have normal patterns of TLR expression, our recent in vivo studies in mice support the significance of these results. We found that expression of pIgR and mucosal secretion of SIgA were significantly reduced in mice genetically deficient in MyD88,⁷ an intracellular adaptor protein that transmits signals from TLR4 and other TLRs that respond to bacterial ligands, as well as the receptors for IL-1 and IL-18. We further demonstrated that pIgR expression is reduced in mice with a targeted deletion of MyD88 only in IECs (Frantz et al., manuscript in preparation), suggesting that MyD88-dependent signaling within epithelial cells is crucial for maintaining optimal pIgR expression. We did not observe marked abnormalities in the architecture of the intestinal epithelium in mice with IEC-targeted depletion of MyD88, as has been reported for mice genetically deficient in MyD88 in all cell types.⁸ However, the dramatic increase in numbers of bacteria in the mesenteric lymph nodes of mice with IEC-targeted depletion of MyD88 suggested that MyD88-dependent signaling in epithelial cells is crucial for maintenance of normal intestinal immunity and barrier function.

A proposed model of bacterial-epithelial cross-talk in the regulation of pIgR expression and dIgA transport is illustrated in Figure 1. A dense layer of mucus, which increases in thickness from the proximal to the distal colon, serves to separate bacteria from direct contact with the epithelial surface.^{9, 10} Secretion of MAMPs by commensal bacteria stimulates TLR signaling and enhances pIgR expression, resulting in enhanced transcytosis of SIgA as well as free SC, which contributes to innate immune functions (see article by Mantis and Corthésy in this issue). SIgA and SC have mucus-binding properties, which serve to trap bacteria in the mucus layer, stimulate biofilm formation, and limit access of bacteria to the epithelial surface.

Figure 1.

Regulation of production of SIgA and free SC in mucosal epithelia. The single-layered epithelium is covered with a thick mucus layer that physically excludes members of the resident microbiota. (1) Stimulation of epithelial Toll-like receptors (TLRs) with microbial-associated molecular patterns activates MyD88-dependent signaling pathways that trigger up-regulation of PIGR gene transcription. Activation of TLRs may also stimulate pIgR transcytosis (2) Newly synthesized pIgR molecules are sorted to the basolateral surface of epithelial cells. (3) Dimeric IgA secreted by lamina propria plasma cells binds to pIgR on the epithelial membrane and stimulates transcytosis. (4) IgA-bound and unoccupied pIgR are transcytosed through epithelial cells. (5) Proteolytic cleavage of pIgR at the apical surface releases SIgA and free SC. (6) Binding of SIgA and SC to luminal bacteria promotes association with the mucin layer and biofilm formation, and prevents direct access of bacteria to the epithelial surface.

Inducible transcription of the PIGR gene

Studies in our laboratories and others over the past 20 years have demonstrated that pIgR expression in mucosal epithelial cells is up-regulated by a number of host cytokines, including IFN-γ, TNF, IL-4 and IL-1 (reviewed in refs. 11, 12). An insight into possible regulatory mechanisms was gained by the observation that pIgR mRNA levels rise slowly in response to cytokine stimulation, peaking around 24 hours. The cytokine-induced increase in pIgR mRNA could be blocked by inhibiting protein synthesis with cycloheximide, suggesting that de novo synthesis of one or more intermediary proteins is required. Molecular cloning of the human PIGR gene revealed the presence of several regulatory elements that bind cytokine-inducible transcription factors; the complex pathways of PIGR gene regulation are summarized in Figure 2. Signaling through the IFN-γ receptor causes activation and nuclear translocation of STAT1 dimers, resulting in de novo transcription of IRF1 and association of IRF1 with a cognate element in exon 1 of the PIGR gene. Stimulation with IL-4 causes nuclear translocation of activated STAT6 dimers, which associate with a complex element in intron 1 of the PIGR composed of a STAT6 binding site, a putative binding site for an as yet-unidentified IL-4-induced co-activator, and a TNF-inducible NF-κB binding site. Interactions among these cytokine-inducible elements in exon 1 and intron 1 of the PIGR gene may be responsible for the observed synergy between IFN-γ, IL-4 and TNF in up-regulation of pIgR expression. The sequences of the exon 1 IRF site and the intron 1 STAT6 and NF-κB sites are identical in the human PIGR and mouse Pigr genes, suggesting evolutionary conservation of these regulatory mechanisms. We subsequently demonstrated that induction of PIGR gene transcription via TLR 3 and 4 signaling involves the same NF-κB element in intron 1 that is induced by TNF,⁴ suggesting cooperativity in PIGR gene regulation by signaling received from microbial products and host cytokines. We recently reported that both the classical and alternative pathways of NF-κB activation are involved in PIGR gene regulation, including the novel discovery that signaling through the lymphotoxin-β receptor up-regulates pIgR.⁵ Experiments with siRNA-mediated knockdown of individual NF-κB subunits suggested that both RelA/p50 and RelB/p52 dimers can activate the NF-κB element in intron 1. It is likely that this NF-κB element is also involved in regulation of pIgR by IL-1, which activates a MyD88-dependent signaling pathway that shares many elements with TLR pathways. Another pro-inflammatory cytokine, IL-17, has recently been shown to enhance pIgR expression in mucosal epithelial cells;¹³ it will be interesting to determine whether IL-17 acts through the intron 1 NF-κB element and/or additional regulatory elements in the PIGR gene. It is significant that expression of pIgR is up-regulated by cytokines characteristic of multiple T cell lineages, including Th1, Th2 and Th17, as well as pro-inflammatory cytokines like TNF and IL-1. The responsiveness of the PIGR gene to such diverse cytokines suggests that the ability to enhance transport of IgA antibodies in response to a wide range of immunological stimuli may have conferred an evolutionary advantage.

Figure 2.

Regulation of PIGR gene transcription by microbial products and host cytokines. Ligation of Toll-like receptors (TLRs) and cytokine receptors results in translocation of activated transcription factors to the nucleus and de novo synthesis of additional transcription factors. The PIGR gene contains binding sites for members of the Interferon Regulatory Factor (IRF), Signal Transducer and Activator of Transcription (STAT) and Nuclear Factor-κB (NF-κB) families of transcription factors. The complex signaling pathways that regulate PIGR gene transcription are described in the text.

Down-regulation of pIgR expression in inflammatory bowel disease

Given the well-documented up-regulation of pIgR expression by pro-inflammatory cytokines, it is paradoxical that expression of pIgR in IECs is down-regulated during intestinal inflammation associated with inflammatory bowel disease (IBD). In a study comparing Crohn’s disease patients with healthy controls, we found that down-regulation of pIgR mRNA in the colonic mucosa was correlated with disease severity.¹⁴ We have subsequently observed that down-regulation of pIgR in colonic epithelial cells is also a feature of ulcerative colitis in humans, and in experimental murine colitis induced by oral administration of dextran sulfate sodium (Frantz et al., manuscript in preparation). We further noted aberrant cellular localization of pIgR in colonic epithelial cells, dysregulated epithelial transcytosis of dIgA, accumulation of IgA in the intestinal lamina propria, and increased levels of circulating IgA in humans and mice with IBD. We hypothesize that inflammation-induced damage to the intestinal epithelium may disrupt intracellular signaling pathways and alter protein trafficking, resulting in profound defects in the pIgR-IgA system. These changes could result in impaired mucosal immunity and increased exposure of the systemic immune system to intestine-derived antigens, further exacerbating inflammation. We and others have reported that expression of pIgR is down-regulated in sporadic colorectal tumors in humans.^15–17 A common feature of these conditions is rapid proliferation of relatively undifferentiated epithelial cells, which may not respond properly to microbial and host factors that maintain pIgR expression under homeostatic conditions and enhance pIgR expression during infections.

Regulation of epithelial transcytosis of pIgR

The pIgR has five extracellular transmembrane domains, a single membrane-spanning helix and an intracellular tail of 103 amino acids (reviewed in refs. 12, 18). After its translation and insertion into the endoplasmic reticulum, the pIgR is sorted through the Golgi and trans-Golgi network and targeted to the basolateral membrane of polarized epithelial cells. Transcytosis of dIgA occurs in three biochemically and morphologically distinct steps: 1) endocytosis from clathrin-coated pits and delivery to basolateral early endosomes; 2) microtubule-dependent translocation to apical recycling endosomes; and 3) delivery from the apical endosomes to the plasma membrane.¹⁹ Proteolytic cleavage of pIgR at the apical plasma membrane ensures that transport of dIgA is unidirectional, although there can be a certain level of recycling at each step. During transcytosis, dIgA becomes covalently bound to the pIgR via a disulfide exchange reaction and the extracellular SC domain of the pIgR remains bound to dIgA in external secretions. The presence of bound SC confers protection against proteases and mucosal anchoring properties to the SIgA molecule (see article by Mantis and Corthésy in this issue).

Intracellular targeting of the pIgR is similar to other integral membrane proteins destined for the apical plasma membrane in polarized epithelial cells, which generally follow an indirect route involving initial targeting the basolateral surface and subsequent transcytosis to the apical surface.²⁰ In the absence of dIgA there is constitutive transcytosis of pIgR, which is the source of free SC in mucosal secretions. However, binding of dIgA to pIgR at the basolateral surface increases the transcytotic rate of the pIgR-dIgA complex by initiating a signaling cascade that activates effector proteins acting on the third step in the transcytosis pathway. The cytoplasmic domain of the pIgR does not contain known signaling motifs, but dimerization of the receptor activates the tyrosine kinase p62^YES, which phosphorylates several substrates including phospholipase Cγ1. Downstream effectors of the phospholipase Cγ1 signaling pathway mediate an increased rate of exocytosis of pIgR-dIgA complexes from apical recycling endosomes.²¹ More recently, it was demonstrated that p62^YES could also phosphorylate the epidermal growth factor (EGF) receptor in an IgA-dependent manner, suggesting that other extracellular signals might also affect transcytosis.²² Indeed, stimulation of cells with EGF itself increased the rate of pIgR-mediated dIgA transport, but the effect was shorter lived than the effect of dIgA. Enhanced transcytosis of pIgR depended on phosphorylation and activation of extracellular regulated kinase (ERK), which in turn was found to phosphorylate the Rab11 effector Rab11-FIP5. However, overstimulation of this pathway, achieved by co-transfection of constitutively active EGFR variants, disrupted epithelial cell polarity and transcytosis rather than enhancing constitutive transcytosis.

The ability of dIgA to stimulate its own transcytosis makes teleological sense, but transcytosis might also be stimulated by other extracellular signals. As described above, members of the resident microbiota enhance the expression of pIgR in a MyD88-dependent fashion; recent data suggest that MAMPs can also stimulate transcytosis of pIgR.²³ Stimulation of a human IEC line with live or dead Escherichia coli or with LPS stimulated both receptor expression and the rate of dIgA transport across polarized epithelial monolayers. Because transcytosis was significantly enhanced prior to increased pIgR expression, the authors concluded that LPS could also directly stimulate transcytosis. Although the signal transduction pathway was not investigated in this study, it is possible that TLR stimulation and dIgA stimulation converge at the point of ERK phosphorylation. Additional stimulation may have been mediated by other components of whole bacteria, such as formyl peptides, which have recently been shown to activate ERK in IECs without stimulating pro-inflammatory pathways.²⁴

Conclusions

SIgA antibodies represent the first line of antigen-specific immune defense protecting the mucosal surfaces against environmental pathogens and antigens, and maintaining homeostasis with the commensal microbiota. The pIgR plays the dual role of transporting locally produced dIgA across mucosal epithelia, and serving as the precursor of SC, a glycoprotein that enhances the immune functions of SIgA. The complex regulation of pIgR expression and transcytosis by host and microbial factors is finely tuned to optimize the role of SIgA in mucosal immunity. Disruption of this regulatory network in disease states like inflammatory bowel disease can result in profound consequences for mucosal homeostasis and systemic sequelae. Future research into the function and regulation of pIgR and SIgA may offer new insights into the prevention and treatment of infectious and inflammatory diseases that originate at mucosal surfaces.